Filtered By:
Condition: Obesity
Drug: Metformin

This page shows you your search results in order of date. This is page number 3.

Order by Relevance | Date

Total 44 results found since Jan 2013.

Metformin associated with better cardiovascular outcomes than other glycaemic therapies
Context A question exists as to whether the outcome of glycaemic treatment of diabetes varies with the agent used; speculation surrounds whether metformin might be preferable to other treatments. Methods Ghotbi and colleagues performed an epidemiological analysis of 8192 obese patients with diabetes at increased cardiovascular risk participating in the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Mortality and a combined cardiovascular outcome of non-fatal myocardial infarction, non-fatal stroke, resuscitation after cardiac arrest or cardiovascular death were compared among those receiving one of the following interv...
Source: Evidence-Based Medicine - May 19, 2014 Category: Internal Medicine Authors: Bloomgarden, Z. T. Tags: Smoking and tobacco, Epidemiologic studies, Drugs: cardiovascular system, Heart failure, Stroke, Hypertension, Diet, Obesity (nutrition), Ischaemic heart disease, Diabetes, Health education, Smoking Therapeutics Source Type: research

Cardiovascular safety of combination therapies with incretin based drugs and metformin compared with a combination of metformin and sulfonylurea in type 2 diabetes mellitus – a retrospective nationwide study
ConclusionIncretin‐based drugs combined with metformin were safe compared with conventional combinations of glucose‐lowering therapy. Use of incretin‐based therapy may be target for strategies to lower cardiovascular risk in type‐2 diabetes, although it should be recognized that the multivariable analysis may not have fully accounted for important baseline differences.
Source: Diabetes, Obesity and Metabolism - May 14, 2014 Category: Endocrinology Authors: Ulrik Madvig Mogensen, Charlotte Andersson, Emil Loldrup Fosbøl, Tina Ken Schramm, Allan Vaag, Nikolai Madrid Scheller, Christian Torp‐Pedersen, Gunnar Gislason, Lars Køber Tags: ORIGINAL PAPER Source Type: research

Association between first‐line monotherapy with sulphonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study
ConclusionsAll‐cause mortality was significantly increased in patients prescribed sulphonylurea compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that first‐line treatment with sulphonylurea monotherapy should be reconsidered.
Source: Diabetes, Obesity and Metabolism - May 8, 2014 Category: Endocrinology Authors: C. Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S. E. Holden, C. J. Currie Tags: ORIGINAL ARTICLE Source Type: research

Combination therapy with metformin plus sulfonylureas versus metformin plus DPP‐4 inhibitors: association with major adverse cardiovascular events and all‐cause mortality
ConclusionsThere was a reduction in all‐cause mortality for patients treated with metformin combined with DPP‐4i versus metformin plus SU, and a similar trend for MACE.
Source: Diabetes, Obesity and Metabolism - April 25, 2014 Category: Endocrinology Authors: C.Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S.E. Holden, C. J. Currie Tags: Original Paper Source Type: research

Association between first‐line monotherapy with sulfonylurea versus metformin and risk of all‐cause mortality and cardiovascular events: a retrospective, observational study
ConclusionsAll‐cause mortality was significantly increased in patients prescribed sulfonylurea compared with metformin monotherapy. Whilst residual confounding and confounding by indication may remain, this study indicates that first‐line treatment with sulfonylurea monotherapy should be reconsidered.
Source: Diabetes, Obesity and Metabolism - April 1, 2014 Category: Endocrinology Authors: C.Ll. Morgan, J. Mukherjee, S. Jenkins‐Jones, S.E. Holden, C.J. Currie Tags: ORIGINAL PAPER Source Type: research

Modeling effects of SGLT‐2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes
ConclusionsOn the basis of simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - February 19, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H. L. Grossman, M. Cohen Tags: ORIGINAL ARTICLE Source Type: research

Modeling Effects of SGLT‐2 Inhibitor Dapagliflozin Treatment vs. Standard Diabetes Therapy on Cardiovascular and Microvascular Outcomes
ConclusionsBased on these simulation results, adding dapagliflozin to currently available treatment options is projected to further decrease the CV and microvascular complications associated with T2DM.
Source: Diabetes, Obesity and Metabolism - January 20, 2014 Category: Endocrinology Authors: J. Dziuba, P. Alperin, J. Racketa, U. Iloeje, D. Goswami, E. Hardy, I. Perlstein, H.L. Grossman, M. Cohen Tags: Original Paper Source Type: research

EBN resources page
Drug and Therapeutics Bulletin (DTB) April, May, June 2013 issues http://dtb.bmj.com HbA1c targets in type 2 diabetes: guidelines and evidence Aims of treatment for type-2 diabetes include minimising long-term complications (eg, cardiovascular disease, blindness, chronic kidney disease, premature mortality) and avoiding the unwanted effects of treatment (eg, severe hypoglycaemia, weight gain). Publication of the UK Prospective Diabetes Study (UKPDS) 33 in 1998 suggested that ‘intensive blood glucose control’ to lower the glycated haemoglobin (HbA1c) in people with type 2 diabetes reduced microvascular disease b...
Source: Evidence-Based Nursing - December 10, 2013 Category: Nursing Authors: Noble, E. b. H. Tags: Diarrhoea, Immunology (including allergy), Drugs: infectious diseases, Urinary tract infections, Stroke, Hypertension, Obesity (nutrition), Cervical cancer, Pregnancy, Reproductive medicine, Colon cancer, Gynecological cancer, Ophthalmology, Complementary Source Type: research

Association of Hypoglycemic Treatment Regimens on Cardiovascular Outcomes in Overweight and Obese Subjects With Type 2 Diabetes: A Substudy of the SCOUT Trial.
CONCLUSIONSIn obese patients with type 2 diabetes and high risk of cardiovascular disease, monotherapy with metformin or diet-only treatment were associated with lower risk of cardiovascular events than treatment with insulin. PMID: 24089540 [PubMed - as supplied by publisher]
Source: Diabetes Care - October 2, 2013 Category: Endocrinology Authors: Ghotbi AA, Køber L, Finer N, James WP, Sharma AM, Caterson I, Coutinho W, Van Gaal LF, Torp-Pedersen C, Andersson C Tags: Diabetes Care Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPP‐IV inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - September 10, 2013 Category: Endocrinology Authors: N. M. Scheller, U. M. Mogensen, C. Andersson, A. Vaag, C. Torp‐Pedersen Tags: ORIGINAL ARTICLE Source Type: research

All‐cause mortality and cardiovascular effects associated with the DPPIV‐inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population
ConclusionIn a retrospective analysis, sitagliptin monotherapy compared with metformin monotherapy was not associated with any statistical significant increased risk of all‐cause mortality or the composite endpoint, but was associated with an increased likelihood of changing glucose‐lowering treatment.
Source: Diabetes, Obesity and Metabolism - August 21, 2013 Category: Endocrinology Authors: Nikolai Madrid Scheller, Ulrik Madvig Mogensen, Charlotte Andersson, Allan Vaag, Christian Torp‐Pedersen Tags: Original Article Source Type: research

Diabetes drugs may be linked to pancreatic cancer
Conclusion This article presents important concerns that glucagon-like peptide-1 (GLP-1) agonists and dipeptidylpeptidase-4 (DPP-4) inhibitors could potentially increase the risk of inflammation and cancerous changes in the pancreas. The agencies that regulate medicines in Europe and the USA are aware of these issues, and told the BMJ that their analyses show increased reporting of pancreatic cancer among people taking these types of drugs. However, the agencies note that it has not been established whether these drugs directly cause the adverse effects seen in the pancreas. Both agencies are reviewing emerging eviden...
Source: NHS News Feed - June 10, 2013 Category: Consumer Health News Tags: Medication Diabetes QA articles Source Type: news

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of the dipetidyl peptidase‐4 inhibitor alogliptin in type 2 diabetes mellitus†
ConclusionThese analyses have not shown a signal of increased CV risk with alogliptin in patients with type 2 diabetes. Future results from the adequately powered EXAMINE trial will definitively assess the CV safety profile of aloglipin in patients with type 2 diabetes mellitus.
Source: Diabetes, Obesity and Metabolism - April 4, 2013 Category: Endocrinology Authors: W. B. White, R. Pratley, P. Fleck, M. Munsaka, M. Hisada, C. Wilson, V. Menon Tags: ORIGINAL ARTICLE Source Type: research